

triamcinolone extended-release (Zilretta)

HCPCS: J3304 Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1mg (Zilretta)

LOB:	MCAL, OneCare (Medicare Part B)
Duration of Approval:	One dose per knee per lifetime
Quantity Limit:	Per FDA-Approved/Compendia-Supported Dosing
MCG Available:	No
DHCS Drug Policy:	No

Requires Prior Authorization (PA)

Zilretta (triamcinolone acetonide extended-release) injection

PA CRITERIA FOR APPROVAL:

1. The member has a diagnosis for an FDA-approved indication (refer to package insert under References) OR a compendia-supported (Drugdex or American Hospital Formulary Service [AHFS]) indication **AND**
2. The medication is prescribed or recommended by a rheumatologist, orthopedic specialist or physiatrist (physical medicine and rehabilitation pain medicine) **AND**
3. The member has documented pain that interferes with functional activities (e.g., ambulation, prolonged standing) **AND**
4. The member has a history of failure, contraindication or reasons for intolerance to TWO alternatives, such as: oral analgesics (e.g., acetaminophen [APAP], oral nonsteroidal anti-inflammatory drugs [NSAIDs] or diclofenac 1% gel) **AND**
5. The member has a history of failure, contraindication or reasons for intolerance to short-acting intra-articular steroid injection (such as Kenalog, Depo-Medrol)

OTHER INFORMATION:

HCPCS	Description	Brand name
J3304	Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg	Zilretta

REFERENCES:

1. Zilretta Prescribing Information. zilrettalabel.com/PI. 11/2024.

UMC Review: 5/2026